Endoprosthesis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The endoprosthesis market is expected to grow from USD 26.77 billion in 2025 to USD 29.56 billion in 2026, and is forecasted to reach USD 50.07 billion by 2031, growing at a CAGR of 11.12% from 2026 to 2031. This report is segmented by Product Type (Knee Endoprostheses, Hip Endoprostheses, and More), Procedure (Total Replacement, and More), Indication (Osteoarthritis, Rheumatoid and Inflammatory Arthritis, and More), End-User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Value (USD).

Global Endoprosthesis Market Trends and Insights

Aging Populations and Rising Osteoarthritis Burden

The endoprosthesis market is supported by an aging population and a growing burden of osteoarthritis. A 2025 study projected continued growth in osteoarthritis prevalence and disability through 2050, with a heavier burden among women and people aged 55 years or older. Hip and knee arthroplasty remains underrepresented in health planning despite its effect on mobility and disability. Demand is likely to become more durable in Japan, South Korea, China, and India as larger, older populations gain access to orthopedic services.

Rising Obesity, Sports Injury, and Post-Traumatic Joint Disease Prevalence

Post-traumatic joint disease adds a younger and more physically demanding patient group to the endoprosthesis market. Road traffic injuries caused 1.19 million deaths each year worldwide, and survivors may experience orthopedic trauma that creates later reconstructive needs. This exposure is important in India, Southeast Asia, and Latin America, where injury burdens are high, and trauma care capacity remains uneven. Greater sports participation also increases ligament and cartilage injuries among patients in their 30s and 40s. A 2025 engineering study found that an auxetic femoral stem design reduced stress shielding by 52.3% in a modeled hip replacement setting. These patients can increase demand for cementless fixation, bone-conserving designs, and materials intended for long service life.

High Implant, Operating Room, and Rehabilitation Costs

High costs remain a restraint on the endoprosthesis market, especially where public insurance coverage is limited. Total joint replacement includes the implant, operating room time, anesthesia, imaging, and rehabilitation. The World Health Organization has described arthroplasty as an essential surgery that remains insufficiently included in global health planning despite its role in treating disability. Custom, revision, and tumor reconstruction implants carry greater unit costs and may not be fully covered under diagnosis-related payment systems. Out-of-pocket costs in Sub-Saharan Africa and rural Southeast Asia can prevent clinically appropriate treatment. Manufacturers need lower-cost lines, government partnerships, and payment approaches that expand access without reducing standards of care.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Robotic-Assisted and Minimally Invasive Arthroplasty
• Growth of Ambulatory Surgical Center and Same-Day Joint Replacement Pathways
• Reimbursement Pressure, Hospital Procurement Consolidation, and Price Compression

Segment Analysis

Knee endoprostheses held 38.26% of the endoprosthesis market share in 2025. The category includes total, partial, revision, and tumor reconstruction options, which support its broad clinical use. Knee osteoarthritis affected 365 million people globally in 2019 and provides a large procedure base for the category. Demand is tied to a condition that often advances over time and can require replacement when nonoperative care is no longer effective. The category also benefits from extensive surgeon training and well-developed care pathways. Its scale makes it central to purchasing decisions at hospitals, orthopedic clinics, and ambulatory surgical centers.

Hip endoprostheses are forecasted to grow at 12.15% CAGR through 2031. Growth is linked to cementless fixation and bearing surface developments that address compromised bone and longer patient life expectancy. Shoulder replacement is also gaining attention as robotic platforms expand to upper-extremity procedures. Stryker placed Mako Shoulder into full commercial release in March 2026, combining planning software, robotic technology, and compatible reversed shoulder implants. Smaller joints remain lower-volume categories, but their complexity can support higher unit values and more specialized clinical requirements.

Total replacement procedures accounted for 40.16% of the endoprosthesis market in 2025. They remain the common choice for advanced hip and knee osteoarthritis because clinical practice, surgeon training, and reimbursement are well established. The procedure has a broad implant portfolio and a large installed base of experienced surgeons. Revision procedures account for less volume but require more complex implants and greater operating expertise. These cases are likely to remain concentrated in academic centers and specialized hospitals.

Partial replacement is forecasted to expand at 12.64% CAGR through 2031. Its growth reflects greater confidence in bone-conserving approaches for selected patients who may need future revision options. Such data gives surgeons and procurement teams a clearer basis for comparing revision risk across devices. Resurfacing remains more limited because registry findings have raised concerns about adverse tissue reactions associated with metal-on-metal bearings. Salvage and tumor reconstruction cases are increasingly using custom additive manufacturing when standard implants cannot match the patient’s anatomy.

Complete Report Scope:

• By Product Type
  • Knee Endoprostheses
  • Hip Endoprostheses
  • Shoulder Endoprostheses
  • Ankle Endoprostheses
  • Elbow Endoprostheses
  • Other Product Types
• By Procedure
  • Total Replacement
  • Partial Replacement
  • Revision Replacement
  • Resurfacing
  • Salvage and Tumor Reconstruction
• By Indication
  • Osteoarthritis
  • Rheumatoid and Inflammatory Arthritis
  • Traumatic Arthritis and Fracture
  • Post-Traumatic Bone Loss
  • Congenital Deformity
  • Other Indications
• By End-User
  • Hospitals and Surgical Centers
  • Ambulatory Surgical Centers
  • Orthopedic Clinics
  • Specialty and Rehabilitation Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 47.34% of the endoprosthesis market share in 2025. The region is supported by high procedure volumes, broad premium implant adoption, and early use of robotic systems. Outpatient primary total knee procedures reached 54% of U.S. procedures in 2024, which shows how strongly site-of-care choices are changing purchasing requirements. The United States remains the largest source of regional volume, while Canada provides predictable demand through provincial systems with stricter price conditions. Mexico is expanding orthopedic capacity through private hospital networks in large cities. These differences require manufacturers to balance premium technology offerings with pricing and reimbursement realities across the region.

Europe is a major endoprosthesis market because Germany, the United Kingdom, France, Italy, and Spain have mature orthopedic systems. National joint registries have a strong influence on purchasing by linking implant selection to survivorship evidence. European Medical Device Regulation requirements increase the importance of post-market clinical follow-up for Class III orthopedic implants. The United Kingdom also has separate post-Brexit requirements, which add regulatory work for suppliers. These systems reward manufacturers that can provide consistent evidence across long follow-up periods.

Asia-Pacific is projected to grow at a 14.21% CAGR through 2031, the fastest rate among geographic segments. China, Japan, India, South Korea, and Australia each contribute different demand conditions, from public procurement to premium registry-led selection. China’s centralized procurement policy reduced average knee prosthesis prices by 82% and strengthened domestic joint suppliers by volume. Japan, South Korea, and Australia offer a different opportunity because older populations and established clinical standards support advanced implant adoption. The Middle East, Africa, and South America remain smaller segments, but private hospital expansion, government health investment, road injury exposure, and lower competitive saturation create room for carefully priced offerings.

List of Companies Covered in this Report:

• Acumed
• Aesculap
• Arthrex
• B. Braun
• Conformis, Inc.
• Corin Group
• DJO Global
• Enovis Corporation
• Enovis' DJO Surgical
• Exactech
• Globus Medical
• Johnson & Johnson
• LimaCorporate S.p.A.
• Medacta International SA
• MicroPort
• Orthofix
• Shoulder Innovations, Inc.
• Smith+Nephew plc
• Stryker
• Zimmer Biomet

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support